LALPATHLAB

** Shares of India's Lal PathLabs DLPA.NS jump 18.58% to 1,621.20 rupees, on course for best day ever, if gains hold

** Diagnostics firm's Q4 revenue rose 16.6% y/y, aided by growth in sample volumes, higher patient additions

** Phillip Capital ("buy", PT: 1,800 rupees) raises FY27 and FY28 earnings estimates by 2% and 7%, respectively, on better-than-expected revenue guidance

** ICICI Securities cuts PT by 40 rupees to 1,460 rupees; estimates 13% revenue and 14.2% EBITDA CAGR over FY26–FY28

** Cuts FY27 and FY28 PAT estimates by ~1% and ~3%, respectively, citing near-term margin pressure from expansion investments

** Trading vols at 2.3 mln shares, nearly 7x the 30-day average

** YTD, stock up ~1.5%

($1 = 94.8687 Indian rupees)

(Reporting by Bipasha Dey in Bengaluru)

((Bipasha.Dey@thomsonreuters.com;))

Refiles to remove extraneous link in paragraph 1

April 30 (Reuters) - Dr Lal Path Labs DLPA.NS reported a 15.5% drop in fourth-quarter profit on Thursday, hurt by higher tax expenses.

Here are some details:

• Consolidated net profit fell to 1.31 billion rupees ($13.8 million) in the quarter ended March, from 1.55 billion rupees a year earlier

• Tax expenses stood at 279 million rupees

• Dr. Lal, which operates 312 clinical labs across India as of March 31, said consolidated revenue rose 16.6% to 7.03 billion rupees, fueled by strong demand for diagnostic tests

• India's largest diagnostics firm by revenue said sample volumes rose 12.9% in the quarter

• Demand for medical tests has been supported by a growing focus on preventive healthcare and expansion by diagnostic chains into smaller cities

• Analysts at Citi said the company continued to report healthy margins, helped by an improved product mix, cost controls, supply-chain efficiencies and greater use of automation

($1 = 94.9100 Indian rupees)

(Reporting by Mridula Kumar in Bengaluru)

((mridula.kumar@thomsonreuters.com))

** Citi Research upgrades Dr Lal PathLabs DLPA.NS to “buy” from “sell”, raises PT to 1,650 rupees from 1,450 rupees

** Brokerage says India’s diagnostics sector moved past COVID-era price wars to more rational competition

** Says diagnostics firm has maintained pricing discipline with no broad hikes despite competition from standalone labs/hospitals

** Expects co to deliver ~10–12% organic revenue growth during FY26-28, driven by core market gains, tier-3/4 cities expansion, richer mix of specialty offerings

** Says margins should remain strong at 28–29%, supported by operating leverage, cost control, supply chain efficiencies

** Robust, debt-free balance sheet supports growth, acquisitions; recent stock correction makes valuations attractive - Citi

** Stock last down 1.8% to 1321 rupees in broader weak market; down 10.9% YTD

(Reporting by Aleef Jahan in Bengaluru)

((aleefjahan.cs@thomsonreuters.com))

Jan 30 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• DR. LAL PATHLABS Q3 CONSOL NET PROFIT 905 MILLION RUPEES

• DR. LAL PATHLABS Q3 CONSOL REVENUE FROM OPERATIONS 6.60 BILLION RUPEES

• DR LAL PATHLABS LTD - DECLARATION OF INTERIM DIVIDEND OF 3.5 RUPEES PER EQUITY SHARE

Source text: ID:nnAZN4S6CPF

Further company coverage: DLPA.NS

((Reuters.Briefs@thomsonreuters.com;;))

Oct 24 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• LAL PATHLABS - CONSIDER ISSUANCE OF BONUS SHARES

Source text: ID:nBSE2R2BZF

Further company coverage: DLPA.NS

((Reuters.Briefs@thomsonreuters.com;;))

** India reducing tax on all medicines from 12% to 5% is a positive move for pharma firms, enabling lower prices and boosting margins by 1%–2%, CLSA notes

** CLSA identifies Torrent Pharma TORP.NS, Abbott India ABOT.NS, Cipla CIPL.NS, Zydus ZYDU.NS, Lupin LUPN.NS and Sun Pharma SUN.NS as key beneficiaries

** All shares currently trading flat

** Medical equipment such as diagnostic kits, blood glucose monitors, surgical devices and bandages will be taxed at 5% from 12% earlier

** CLSA says cut will be positive for diagnostics chains like Dr Lal Pathlabs DLPA.NS, also marginally positive for hospital chains; CLSA's top pick is Apollo Hospitals APLH.NS

** DLPA, APLH rise 1.2% and 1.8%, respectively

** YTD, all stocks rise except Lupin and Sun, which have fallen ~18% and 16.7%, respectively vs pharma index's .NIPHARM 6.5% decline

(Reporting by Urvi Dugar)

((UrviManoj.Dugar@thomsonreuters.com))

April 25 (Reuters) - Dr Lal Path Labs DLPA.NS, India's largest diagnostics firm by revenue, reported fourth-quarter profit above expectations on Friday as strong demand for its bundled test packages lifted growth amid rising health awareness in the country.

The company's consolidated net profit jumped 83.2% year-on-year to 1.55 billion rupees (about $18 million) in the quarter ended March 31, beating analysts' average estimate of 1.02 billion rupees, as per data compiled by LSEG.

Dr Lal's shares, which were trading down 1.2%, jumped nearly 6% after results.

A rising emphasis on preventive healthcare, along with the expansion of diagnostics firms like Dr Lal Path Labs into smaller cities, has fueled demand for medical tests, especially in urban India.

Moreover, the company benefited from strong demand for its bundled tests offerings, which combine tests for multiple conditions, such as diabetes and thyroid, under one, analysts said.

Dr Lal, which operates about 300 clinical labs across India, saw a 9.5% y/y rise in sample volume in the reported quarter, taking its total revenue from operations 10.5% higher to 6.03 billion rupees. Analysts expected revenue to come in at 6.04 billion rupees.

Rival Metropolis Healthcare METP.NS will report its March-quarter results in the coming weeks.

($1 = 85.4100 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Sumana Nandy)

((Kashish.Tandon@thomsonreuters.com; 8800437922;))

April 15 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• DR. LAL PATHLABS LTD - LAUNCHES ADVANCED TEST FOR AMYLOIDOSIS

Source text: ID:nNSEsZfqN

Further company coverage: DLPA.NS

((reuters.briefs@thomsonreuters.com;))

** Shares of Metropolis Healthcare Ltd METP.NS rise 4.4% to 1,813.75 rupees

** Medical diagnostics firm reported a 15.5% rise in Q3 profit on higher sales of costlier tests after market hours on Tuesday; rev up 10%

** METP and larger rival Dr Lal PathLabs DLPA.NS rated "Hold", while analysts rate smaller rival Vijaya Diagnostic VIJA.NS "Buy" - LSEG

** Stock trims YTD losses to 12.8%, but trails DLPA's ~7% loss and VIJA's 11% climb this year

(Reporting by Nandan Mandayam in Bengaluru)

((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))

Jan 30 (Reuters) - India's Dr Lal Path Labs DLPA.NS reported a 19% jump in its third-quarter profit on Thursday, led by continued demand for its bundle test offerings, sending its shares 3% higher.

The company's consolidated net profit rose to 967 million rupees ($11.2 million) in the three months to Dec. 31, from 813 million rupees a year earlier, but fell short of analysts' estimate of 976.9 million rupees, according to data compiled by LSEG.

An increasing awareness around health and wellness, coupled with the expansion of diagnostics firms such as Dr Lal Path into smaller cities, has boosted demand for medical tests.

The company, which operates about 300 testing labs, said the number of samples tested grew 10% during the quarter.

Dr Lal Path has also benefited from strong demand for its bundle test offerings, which combine tests for multiple diseases such as hyperthyroidism and diabetes, analysts said.

The company's revenue from operations met analysts' estimates and climbed about 11% to 5.97 billion rupees.

It declared a dividend of six rupees per share for the fiscal year 2025.

Rival Metropolis Healthcare METP.NS is set to report its third-quarter results next week.

($1 = 86.5630 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza and Mrigank Dhaniwala)

((Kashish.Tandon@thomsonreuters.com; 8800437922;))

Dec 19 (Reuters) - Max India Ltd MAII.NS:

• ANTARA SENIOR CARE ANNOUNCES STRATEGIC COLLABORATION WITH DR. LAL PATHLABS

• PARTNERSHIP TO JOINTLY OFFER DIAGNOSTIC SERVICES TO SENIORS

Source text: ID:nBSEb848Lc

Further company coverage: MAII.NS

((Reuters.Briefs@thomsonreuters.com;;))

Oct 23 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• Q2 CONSOL NET PROFIT 1.29 BILLION RUPEES; IBES EST. 1.26 BILLION RUPEES

• Q2 CONSOL REVENUE FROM OPERATIONS 6.60 BILLION RUPEES; IBES EST. 6.72 BILLION RUPEES

• DIVIDEND 6 RUPEES PER SHARE

• OM PRAKASH MANCHANDA WILL BE STEPPING DOWN AS MANAGING DIRECTOR

Source text for Eikon: [ID:]

Further company coverage: DLPA.NS

((Reuters.Briefs@thomsonreuters.com;;))

** Shares of pathology services provider Dr. Lal Pathlabs DLPA.NS close up 0.4% at 3,311 rupees

** Nomura flags relatively fewer dengue cases in Jan-Sept, particularly in Delhi NCR which accounted for almost a third of DLPA's FY24 revenue

** Number of dengue cases in Delhi in the period was less than half of last year, Nomura said, citing news channel ABP live

** DLPA Q2 earnings due on Wednesday; Nomura expects Q2 revenue to rise 10.5% Y/Y, slower than the 11.3% growth in Q1

** Historically, co's Q2 rev growth is higher than Q1, brokerage says

** Nomura rates DLPA 'buy' with Sept 2025 TP of 3,720 rupees

** Stock up ~29% YTD

(Reporting by Vijay Malkar)

((VijayDattaram.Malkar@thomsonreuters.com;))

Sept 19 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• LAL PATHLABS - KENYA UNIT HAS BEEN DISSOLVED

Source text for Eikon: [ID:]

Further company coverage: DLPA.NS

((Reuters.Briefs@thomsonreuters.com;))

Dr. Lal PathLabs Ltd DLPA.NS:

• LAL PATHLABS- VED PRAKASH GOEL DESIGNATED AS GROUP CHIEF FINANCIAL OFFICER

Source text for Eikon: ID:nNSEbMbNht

Further company coverage: DLPA.NS

Aug 7 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• Q1 CONSOL NET PROFIT 1.06 BILLION RUPEES; IBES PROFIT EST. 992.7 MILLION RUPEES

• Q1 CONSOL REVENUE FROM OPERATIONS 6.02 BILLION RUPEES; IBES EST. 6.03 BILLION RUPEES

• DECLARED DIVIDEND OF 6 RUPEES PER SHARE

Source text for Eikon: [ID:]

Further company coverage: DLPA.NS

((Reuters.Briefs@thomsonreuters.com;))

** Shares of Thyrocare Technologies THYO.NS gain 10% in heavy trading, set for third straight session of gain

** Diagnostics firm reported ~40% Y/Y climb in Q1 consol net profit on strong testing demand; rev from ops climbed 16% Y/Y

** Trading volume more than 8x the 30-day moving average

** Stock up 11% YTD vs bigger rival Dr. Lal PathLabs' DLPA.NS ~17% rise

(Reporting by Kashish Tandon in Bengaluru)

((kashish.tandon@thomsonreuters.com))

** Shares of Dr. Lal PathLabs DLPA.NS up 6.04% to 2,489.8 rupees - its highest since early Feb.

** At least eight brokerages up TPs on stock post Friday's Q4 profit rise, including Nomura - LSEG

** Stock settled 5.2% higher in the previous session

** Nomura upgrades rating on stock to "Buy" from "Neutral" reflecting improved growth visibility, limited downside risks in valuation of stock

** Raises FY25-26 earnings estimates by 6%-8% on higher rev, gross margin and operating leverage

** Morgan Stanley keeps TP of 2,681 rupees and rating "Overweight" unchanged

** Prefers DLPA for its strong execution record, remains cautious on patient growth and tests/patients trajectory

** Analysts avg rating on stock is "Hold", their median PT on stock is 2,600 rupees

** Stock down 3.4% YTD

(Reporting by Manvi Pant in Bengaluru)

((Manvi.Pant@thomsonreuters.com; +918447554364;))

** Shares of Dr. Lal PathLabs Ltd DLPA.NS up 6.6% at 2,379.60 rupees

** Medical diagnostics firm reports 49% jump in Q4 consolidated net profit, with revenue growing faster than expenses

** Stock was up 4% ahead of results

** Around 570,000 shares traded, 2x 30-day avg volume

** Analysts covering DLPA rate it "hold" on avg, same as Metropolis Healthcare METP.NS, vs "buy" for Vijaya Diagnostic Centre VIJA.NS - LSEG data

** DLPA reduces YTD losses to under 8% but trails METP's 4% rise and VIJA's 17% growth

(Reporting by Nandan Mandayam in Bengaluru)

((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))

** Shares of Metropolis Healthcare METP.NS rise as much as 7.4% to 1,933.50 rupees, highest since May 18, 2022

** Diagnostic services co says revenue grew ~15% Y/Y in Q4FY24

** Adds, EBITDA margins show consistent upward trend both Q/Q and Y/Y, driven by higher volumes, price increase

** Stock on track to gain for fifth straight session

** More than 1.6 mln shares traded as of 10:51 a.m. IST, 5.6x their 30-day moving avg; busiest day yet since Feb. 6

** Mean rating of 13 analysts is "hold"; median PT 1,670 rupees, while bigger peer Dr. Lal Pathlabs DLPA.NS is "sell" - LSEG data

** METP last up 4.3%, adding to YTD gains of ~11.9%; DLPA down 8%

(Reporting by Meenakshi Maidas in Bengaluru)

((meenakshi.maidas@thomsonreuters.com;))

April 1 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• GOT ASSESSMENT ORDER WHEREIN DEDUCTION CLAIMED ON ACCOUNT OF ESOP EXPENSES OF 326.6 MILLION RUPEES DISALLOWED

Source text for Eikon: ID:nNSE6yZLrB

Further company coverage: DLPA.NS

((Reuters.Briefs@thomsonreuters.com;;))

** Dr. Lal PathLabs' shares DLPA.NS jump 5% to 2,236 rupees

** Stock set for its steepest pct rise since early Nov

** Kotak Institutional Equities double upgrades to "add" from "sell", lifts fair value to 2,360 rupees from 1,975 rupees

** Brokerage expects improvement in pricing trends for diagnostics and views new CEO appointment as a positive

** Stock tumbled ~13% in 9 sessions since CEO left on March. 4; but has clawed back losses to ~9% since a new CEO was named on March 17

** Still, Kotak's new FV is 3.8% discount to analysts' median PT, per LSEG data

** Analysts avg rating on DLPA is "sell", while it is "hold" for peers Dr. Reddy's Labs REDY.NS and Metropolis Healthcare METP.NS

(Reporting by Manvi Pant in Bengaluru)

((Manvi.Pant@thomsonreuters.com; +918447554364;))

** Shares of diagnostic services provider Dr. Lal Pathlabs DLPA.NS edge up 0.4%

** UBS analysts say co has potential to beat management's EBITDA margin guidance of 26%-27%

** Believes it would reinvest any additional margins into growth opportunities

** DLPA currently has 9 bln rupees in cash; UBS estimates co to report 33% CAGR to 28 bln rupees by FY28

** "Believe Lal Pathlabs has potential to increase EBITDA margin 250-300 basis points in same period if it maintains current rate of investment" - UBS

** Also expects steady pricing environment to aid in steady margins and revenue growth

** UBS maintains "buy" rating and target price at 2,900 rupees
** Avg recommendation on stock is a "sell;" the median TP is 2,452 rupees as per LSEG data

** DLPA is up nearly 3% so far this week, set to snap four straight weeks of losses

(Reporting by Anisha Ajith in Bengaluru)

((anisha.ajith@thomsonreuters.com))

March 18 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• DR. LAL PATHLABS - GETS TAX DEMAND OF 26.3 MILLION RUPEES

Source text for Eikon: ID:nBSE3Ww5CL

Further company coverage: DLPA.NS

((Reuters.Briefs@thomsonreuters.com;))

March 17 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• APPROVED THE RE-DESIGNATION OF SHANKHA BANERJEE BY APPOINTING HIM AS CEO WITH EFFECT FROM MAY 21, 2024.

Source text for Eikon: ID: nNSE6BBmpx

Further company coverage: DLPA.NS

((Reuters.Briefs@thomsonreuters.com;))

** Shares of Dr. Lal PathLabs DLPA.NS fall 1.7% to 2,294.1 rupees

** Co said Bharath U resigns as chief executive officer

** CEO added that he will take up external assignment post resignation

** Seventeen analysts covering the stock on avg have a "Sell" rating; median PT is 2,452.5 rupees - LSEG data

** DLPA trading below its 50-day, 100-day and 200-day simple moving averages since Feb.

** Stock down ~11% so far this quarter; set to snap three consecutive quarterly gains if trend holds

(Reporting by Ashna Teresa Britto in Bengaluru)

((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))

Feb 1 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• DR. LAL PATHLABS DEC-QUARTER CONSOL NET PROFIT 813 MILLION RUPEES

• DR. LAL PATHLABS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.39 BILLION RUPEES

• DR. LAL PATHLABS YEAR AGO DEC-QUARTER NET PROFIT 528 MILLION RUPEES, REVENUE 4.89 BILLION RUPEES

• DR. LAL PATHLABS LTD - DIVIDEND 12 RUPEES PER SHARE

Source text for Eikon: [ID:]

Further company coverage: DLPA.NS

((reuters.briefs@thomsonreuters.com;))

** Shares of Indian diagnostic firms including Dr. Lal PathLabs DLPA.NS, Metropolis Healthcare METP.NS and Thyrocare Technologies THYO.NS rise over 4%

** METP hits its peak since April 5, 2022, and THYO achieves its highest level since Dec. 22, 2022

** DLPA posts biggest intraday gain since Nov. 3

** Between 2020 and 2021, diagnostic firms in India made profits from testing for Coronavirus infection among millions of patients; since India eased pandemic curbs, profits have waned

** India reports 594 new daily cases of COVID, up about 151% from a week ago - Health Ministry data

** "During the COVID-19 pandemic, diagnostic companies emerged as major beneficiaries, benefiting from the surge in demand for COVID testing. Alongside this, there was an increase in the demand for various medical supplies, including devices, injections, oximeters, and more," says Abdulkader Puranwala, assistant vice president, ICICI Securities

(Reporting by Navamya Ganesh Acharya and Rama Venkat in Bengaluru)

((Navamya.GaneshAcharya@thomsonreuters.com; +91 8805175330 ;))

Nov 2 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS:

• SEPT-QUARTER CONSOL NET PROFIT 1.09 BILLION RUPEES VERSUS PROFIT 717 MILLION RUPEES YEAR AGO

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 6.01 BILLION RUPEES VERSUS 5.34 BILLION RUPEES YEAR AGO

Further company coverage: DLPA.NS

((Reutersbriefs@thomsonreuters.com;))